HER2-specific immunotoxins constructed based on single-domain antibodies and the improved toxin PE24X7
Author:
Funder
Natural Science Foundation of Tianjin city of China
Science and Technology Support Funding of Tianjin city of China
Publisher
Elsevier BV
Subject
Pharmaceutical Science
Reference44 articles.
1. Advances in anticancer immunotoxin therapy;Alewine;Oncologist,2015
2. Nanobodies and cancer: current status and new perspectives;Allegra;Cancer Invest.,2018
3. Treatment of HER2-positive breast cancer: current status and future perspectives;Arteaga;Nat. Rev. Clin. Oncol.,2011
4. Strategies and challenges for the next generation of antibody–drug conjugates;Beck;Nat. Rev. Drug. Discov.,2017
5. Next generation antibody drugs: pursuit of the 'high-hanging fruit';Carter;Nat. Rev. Drug. Discov.,2018
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Emerging paradigms and recent progress in targeting ErbB in cancers;Trends in Pharmacological Sciences;2024-06
2. Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with Pseudomonas Exotoxin Catalytic Domain for Cancer Therapeutics;Molecules and Cells;2023-12
3. Design and construction of scFv-PE35KDEL as a novel immunotoxin against human epidermal growth factor receptor 2 for cancer therapy;Biotechnology Letters;2023-02-20
4. Emerging trends in immunotoxin targeting cancer stem cells;Toxicology in Vitro;2022-09
5. Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment;Frontiers in Immunology;2022-01-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3